Newsroom press releases

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)

Products Molecular

Download

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)

Other

Download

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)

Financial Data

Download

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)

Financial Data

Download

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)

Acquisition / Partnership

Download

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)

Products Molecular

Download

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)

Financial Data

Download

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)

Products Molecular

Download

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)

Acquisition / Partnership

Download

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)

Products Molecular

Download

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)

Financial Data

Download

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)

Acquisition / Partnership

Download

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)

Acquisition / Partnership

Download

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)

Products Immunodiagnostic

Download

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)

Products Immunodiagnostic

Download

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)

Financial Data

Download

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)

Financial Data

Download

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)

Products Immunodiagnostic

Download

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)

Products Immunodiagnostic

Download

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)

Financial Data

Download

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)

Products Molecular

Download

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)

Products Immunodiagnostic

Download

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)

Financial Data

Download

29/10/13 - 1:00

DiaSorin signes a 5-year agreement with Roche (432.42 KB)

Acquisition / Partnership

Download

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)

Products Immunodiagnostic

Download

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)

Products Immunodiagnostic

Download

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)

Products Immunodiagnostic

Download

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)

Financial Data

Download

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)

Products

Download

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)

Products Immunodiagnostic

Download

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)

Products Immunodiagnostic

Download

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)

Products Immunodiagnostic

Download

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)

Financial Data

Download

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)

Financial Data

Download

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)

Financial Data

Download

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)

Products Immunodiagnostic

Download

02/04/13 - 2:00

DiaSorin signs an agreement with Seegene (243.64 KB)

Acquisition / Partnership

Download

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)

Financial Data

Download

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)

Financial Data

Download

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)

Financial Data

Download

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)

Products Immunodiagnostic

Download

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)

Financial Data

Download

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)

Financial Data

Download

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)

Financial Data

Download

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)

Products Immunodiagnostic

Download

Newsroom press releases

Select year

Newsroom press category

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)

Resignation of a Strategic Executive of the Company (233.58 KB)

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)

DiaSorin - Annual General Meeting 2016 (421.04 KB)

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)

The Board of Directors approves the results for FY'16 (1.13 MB)

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)

The Board of Directors approves the Q3'13 Results (766.57 KB)

DiaSorin signes a 5-year agreement with Roche (432.42 KB)

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)

The Board of Directors approves the results for the H1 '13 (386.67 KB)

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)

The Board of Directors approves the results for Q1'13 (763.61 KB)

Compensation Commitee-Errata corrige (179.38 KB)

Shareholders' meeting approves FY Results 2012 (57.22 KB)

FDA approves the Aldosterone assay (439.58 KB)

DiaSorin signs an agreement with Seegene (243.64 KB)

The BoD approves FY 2012 results (477.24 KB)

Notification of changes in share capital (46.86 KB)

Notice availability By-Laws (36.87 KB)

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)

Notification of changes in share capital (46.89 KB)

Notice availability By-Laws (139.13 KB)

The Board of Directors approves the results for the FY '12 (477.24 KB)

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)

Price Sensitive